Abstract
The use of multiagent chemotherapy has led to improved survival for osteosarcoma patients. Infusion of cisplatin by the intraarterial route in order to devitalize the primary tumor more effectively has been advocated in this context. While systemic drug levels do not seem to be compromised by this regional approach, the envisioned increase in platinum content of osteosarcoma tissue has not been substantiated.
As far as clinical results are concerned, neither a comparison of various protocols including cisplatin by either intraarterial or intravenous application, nor the only controlled study dealing with the subject (COSS 86), were able to demonstrate a correlation between the route of cisplatin administration and tumor response to chemotherapy.
Therefore, the use of the intraarterial route for cisplatin treatment of osteosarcoma cannot be considered standard therapy but is still an investigational approach without proven benefits. In addition, the risk of side effects and the increased cost of this procedure should be considered before deciding to use intraarterial treatment for osteosarcoma.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bacci G, Avella M, Brach del Prevert A, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results. Chemiotherapia 7:138–142, 1988.
Benjamin RS, Raymond AK, Carrasco CH, et al. Primary chemotherapy of osteosarcoma of the extremities with systemic adriamycin and intra-arterial cisplatinum. Proc Am Soc Clin Oncol 8, abstr. 1251, 1988.
Jaffe N, Raymond AK, Ayala A, et al. Effect of cumulative courses of intraarterial cis-diamminedichloroplatinum-II on the primary tumor in osteosarcoma. Cancer 63:63–67, 1989.
Sierrasesumaga L, Bilbao J, Martin Algarra S, et al. Neoadjuvant chemotherapy with intraarterial (IA) cisplatinum (CDDP) and intravenous adriamycin (ADR) prior to limb sparing tumor resection plus chemotherapy in the treatment of osteosarcoma (OS). ECCO-4. Fourth European Conference on Clinical Oncology and Cancer Nursing, November 1–4, 1987, Madrid, Federation of European Cancer Societies, 1987, p 235.
Weiss A, Lachmann R, Berman J. (Intra-arterial preoperative chemotherapy for osteosarcoma. Proc Am Soc Clin Oncol 8:321, abstr. 1250), 1989.
Malawer M, Reaman G, Prienbat D, et al. Impact of a short course (2 cycles) of neoadjuvant chemotherapy with cisplatinum (DDP) and adriamycin (ADR) on the choice of surgical procedure for high-grade bone sarcomas of the extremities. Proc Am Soc Clin Oncol 8:320 (abstr. 1245), 1989.
Stephens FO, Tattersall MH, Marsden W, et al. Regional chemotherapy with the use of cisplatin and doxorubicin as primary treatment for advanced sarcomas in shoulder, pelvis, and thigh. Cancer 60:724–735, 1987.
Stine KC, Hockenberry MJ, Harrelson J, et al. Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma. Cancer 63:848–853, 1989.
Trapeznikov NN, Yerimina LA, Amiraslanov AT, Sinukov PA. Management of osteosarcoma patients. Semin Surg Oncol 2:1–16, 1986.
Epelman S, Petrilli AS, Franco EL. Factors influencing survival of patients with nonmetastatic osteosarcoma treated with intra-arterial cisplatinum. Proc Am Soc Clin Oncol 6: abstr. 877, 1987.
Estrada J, Greenberg H, Walling AK, et al. Control of pelvic osteosarcoma (OS) with intraarterial (IA) chemotherapy and radiation therapy (XRT). Proc Am Soc Clin Oncol 7: abstr. 1075, 1988.
Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS 86). Cancer 66:1703–1710, 1990.
Kahn CE Jr., Messersmith RN, Samuels BL. Brachial plexopathy as a complication of intraarterial cisplatin chemotherapy. Cardiovasc Intervent Radiol 12:47–49, 1989.
Jacobs SC, Menashe DS, Mewissen MW, Lipchik ED. Intraarterial cisplatin infusion in the management of transitional cell carcinoma of the bladder. Cancer 64:388–391, 1989.
Bland KI, Kimura AK, Brenner DE, et al. A phase II study of the efficacy of diam-minedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 209:73–80, 1989.
Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498–504, 1984.
Brock N, Pohl J. The basis of modern ifosfamide therapy. Introduction. Contrib Oncol 2:1–11, 1987.
Eilber F, Guiliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5:21–26, 1987.
Jaffe N. Subcutaneous reaction due to intra-arterial infusion of anthracycline. Cancer Treat Rep 68:818, 1984.
Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 2:617–623, 1984.
Hecquet B, Vennin P, Fournier C, Poissonier B. Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer. Cancer Res 47:6134–6137, 1987.
Ratto GB, Mereu C, Vannuzi M, Fulco RA. Pharmacokinetics of cisplatin pulmonary artery infusion. Fourth International Congress on Advances in Regional Cancer Therapy, June 5–7, 1989, Berchtesgaden, FRG, Cyanamid-Lederle, Arzneimittel GmbH and Co., F10, 1989.
Wile AG, Kar R, Cohen RA, et al. The pharmacokinetics of cisplatin in experimental regional chemotherapy. Cancer 59:695–700, 1987.
Mangues Baffaluy R. Pharmacokinetic advantage of the cisplatin intra-arterial administration over intravenous route: experimental and clinical study. Diss Abstr Int (C)50:282, 1989.
Shani J, Bertram J, Russell C, et al. Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans. Cancer Res 49:1877–1881, 1989.
Bielack S, Erttmann R, Looft G, et al. Platinum disposition after intraarterial and intravenous infusion of cisplatinum for osteosarcoma. Cancer Chemother Pharmacol 24:376–380, 1989.
Stewart DJ, Mikhael NZ, Nair RC, et al. Platinum concentrations in human tumor autopsy samples. Am J Clin Oncol 11:152–158, 1988.
Jakowatz J, Snyder L, Ginn G, et al. Effect of route and schedule of cisplatin administration. Proc Am Soc Clin Oncol 8: abstr. 254, 1989.
Kishimoto S, Fukushima S, Hayashi Y, et al. Basic studies on optimal delivery rate of cisplatin. Gan Kagaku Ryohu 16:2788–2791, 1989.
Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS 82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337, 1988.
Picci P, Bacci G, Capanna R, et al. Neoadjuvant chemotherapy for osteosarcoma—results of a prospective study. In: Recent Concepts in Sarcoma Treatment. Ryan JR, Baker LH, Eds. Kluwer Academic, Dordrecht, 1988, pp 291–295.
Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. Cancer Treat Rep 70:1431–1432, 1986.
Ruggieri P, Picci P, Marangolo M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremies (OS): preliminary results in 116 patients (PTS) treated preoperatively with methotrexate (MTX) (IV), cisplatinum (CDP) (IA) and adriamycin (ADM). Proc Am Soc Clin Oncol 9:310 (abstr. 1199), 1990.
Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733, 1979.
Brunat-Mentigny M, Demaille MC, Quitana E, et al. The reproduction in France of Rosen’s protocol for osteosarcomas. Bull Cancer (Paris) 75:201–206, 1988.
Kalifa C, Mlika N, Dubousset J, et al. Experience with protocol T10 in the pediatric service at the Gustave-Roussy institute. Bull Cancer (Paris) 75:207–211, 1988.
Solheim OP. Adjuvant chemotherapy in patients with osteosarcoma. ECCO-4. Fourth European Conference on Clinical Oncology and Cancer Nursing, November 1–4, 1987, Madrid, Federation of European Cancer Societies, 1987, p 236.
Provisor A, Nachman J, Krailo M, et al. Treatment of non-metastatic osteosarcoma (OS) of the extremities with pre-and post-operative chemotherapy. Proc Am Soc Clin Oncol 6:217, 1987.
Green DM, Brecher ML, Douglass HO Jr., et al. The treatment of pediatric patients with osteosarcoma of an extremity. Does pre-operative intra-arterial chemotherapy affect prognosis? Proc Am Assoc Cancer Res 28:219, 1987.
Eilber FR, Giuliano AE, Huth JF, et al. Intravenous (IV) versus intraarterial (IA) adriamycin, 2800r radiation and surgical excision for extremely soft tissue sarcomas: a randomized prospective trial. Proc Am Soc Clin Oncol 9:309 (abstr. 1194), 1990.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bielack, S.S., Bieling, P., Erttmann, R., Winkler, K. (1993). Intraarterial chemotherapy for osteosarcoma: Does the result really justify the effort?. In: Humphrey, G.B., Koops, H.S., Molenaar, W.M., Postma, A. (eds) Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Cancer Treatment and Research, vol 62. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3518-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3518-8_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6561-7
Online ISBN: 978-1-4615-3518-8
eBook Packages: Springer Book Archive